Cargando…

Novel Mutations Found in Individuals with Adult-Onset Pompe Disease

Pompe disease, or glycogen storage disease II is a rare, progressive disease leading to skeletal muscle weakness due to deficiency of the acid α-1,4-glucosidase enzyme (GAA). The severity of disease and observed time of onset is subject to the various combinations of heterozygous GAA alleles. Here w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aung-Htut, May T., Ham, Kristin A., Tchan, Michel C., Fletcher, Sue, Wilton, Steve D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073677/ https://www.ncbi.nlm.nih.gov/pubmed/32012848 http://dx.doi.org/10.3390/genes11020135

Ejemplares similares

Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease
por: Aung-Htut, May Thandar, et al.
Publicado: (2020)

A Splice Intervention Therapy for Autosomal Recessive Juvenile Parkinson’s Disease Arising from Parkin Mutations
por: Li, Dunhui, et al.
Publicado: (2020)

Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1
por: Ham, Kristin A., et al.
Publicado: (2020)

In Vitro Validation of Phosphorodiamidate Morpholino Oligomers
por: Aung-Htut, May T., et al.
Publicado: (2019)

Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing
por: McIntosh, Craig S., et al.
Publicado: (2019)

Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides
por: Ham, Kristin A., et al.
Publicado: (2021)

Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides
por: Aung-Htut, May T., et al.
Publicado: (2019)

Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides
por: Aung-Htut, May T., et al.
Publicado: (2019)

Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations
por: McIntosh, Craig S., et al.
Publicado: (2021)

Consequences of Making the Inactive Active Through Changes in Antisense Oligonucleotide Chemistries
por: Zaw, Khine, et al.
Publicado: (2019)

S1.3 Adult-onset Pompe disease
por: Di Iorio, Giuseppe, et al.
Publicado: (2011)

Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations
por: Cale, Jessica M., et al.
Publicado: (2023)

A novel homozygous mutation at the GAA gene in Mexicans with early-onset Pompe disease
por: ESMER, CARMEN, et al.
Publicado: (2013)

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies
por: McIntosh, Craig S., et al.
Publicado: (2021)

Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies
por: Toh, Zhi Yon Charles, et al.
Publicado: (2016)

Hypothyroidism in late-onset Pompe disease
por: Schneider, Joseph, et al.
Publicado: (2016)

Late‐onset Pompe disease with a novel mutation and a rare phenotype: A case report
por: Si, Xiaoli, et al.
Publicado: (2022)

Quantitative analysis of upright standing in adults with late-onset Pompe disease
por: Valle, Maria Stella, et al.
Publicado: (2016)

Adult‐onset Pompe's disease presenting with insidious hypercapnic respiratory failure
por: O'Callaghan, Cara, et al.
Publicado: (2016)

PDGF-BB serum levels are decreased in adult onset Pompe patients
por: Fernández-Simón, Esther, et al.
Publicado: (2019)

Late-Onset Pompe Disease with Nemaline Bodies
por: Frezza, E., et al.
Publicado: (2018)

Late-onset Pompe disease manifests in the brain
por: Finsterer, Josef
Publicado: (2019)

Pregnancy Outcomes in Late Onset Pompe Disease
por: Goker-Alpan, Ozlem, et al.
Publicado: (2020)

Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand
por: Ngiwsara, Lukana, et al.
Publicado: (2019)

Familial adult-onset Pompe disease associated with unusual clinical and histological features
por: MAGGI, LORENZO, et al.
Publicado: (2013)

Recommendations for Infantile-Onset and Late-Onset Pompe Disease: An Iranian Consensus
por: Fatehi, Farzad, et al.
Publicado: (2021)

Late-Onset Glycogen Storage Disease Type II (Pompe's Disease) with a Novel Mutation: A Malaysian Experience
por: Fu Liong, Hiew, et al.
Publicado: (2014)

Identification of Seven Novel Mutations in the Acid Alpha-glucosidase Gene in Five Chinese Patients with Late-onset Pompe Disease
por: Liu, Hua-Xu, et al.
Publicado: (2018)

Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents
por: Wilton, Steve D, et al.
Publicado: (2011)

Breakpoint junction features of seven DMD deletion mutations
por: Keegan, Niall P., et al.
Publicado: (2019)

S1.2 The pediatrician and the early onset Pompe disease
por: Fecarotta, Simona, et al.
Publicado: (2011)

Fatigue: an important feature of late-onset Pompe disease
por: Hagemans, M. L. C., et al.
Publicado: (2007)

Bone density in patients with late onset Pompe disease
por: Papadimas, George, et al.
Publicado: (2012)

The Outcome of Infantile Onset Pompe Disease in South of Iran
por: Moravej, Hossein, et al.
Publicado: (2016)

The infantile-onset form of Pompe disease: an autopsy diagnosis
por: dos Santos, Otávio César Cruz, et al.
Publicado: (2015)

Atypical Infantile-onset Pompe Disease with Hypertrophic Cardiomyopathy
por: Quan, Jun-Jun, et al.
Publicado: (2017)

A genetic modifier of symptom onset in Pompe disease
por: Bergsma, Atze J., et al.
Publicado: (2019)

Response: Late-onset Pompe disease manifests in the brain
por: Schneider, Ilka, et al.
Publicado: (2019)

Is the brain involved in patients with late‐onset Pompe disease?
por: van den Dorpel, Jan J. A., et al.
Publicado: (2022)

Treatment Dilemma in Children with Late-Onset Pompe Disease
por: Faraguna, Martha Caterina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r0gd3suml3hhldustrqgpodmd5